Acceder

Participaciones del usuario condep1002

condep1002 03/08/16 13:59

Ha respondido al tema Farmas USA

https://biotechinvesting.info/2016/08/01/amarin-amrn-and-terratech-trtc/

Ir a respuesta

condep1002 30/07/16 10:02

Ha respondido al tema Farmas USA

http://www.fool.com/investing/2016/07/12/3-risky-biotech-stocks-that-could-make-you-rich.aspx?

Ir a respuesta

condep1002 17/07/16 15:09

Ha respondido al tema Farmas USA

http://www.fool.com/investing/2016/07/12/3-risky-biotech-stocks-that-could-make-you-rich.aspx

Ir a respuesta

condep1002 02/07/16 10:20

Ha respondido al tema Farmas USA

AMRN http://www.pennystocksweekly.com/fundamental_stock_reports.php?symbol=AMARIN

Ir a respuesta

condep1002 04/06/16 18:43

Ha respondido al tema Farmas USA

http://www.pennystocksweekly.com/fundamental_stock_reports.php?symbol=AMARIN AMRN

Ir a respuesta

condep1002 01/06/16 12:43

Ha respondido al tema Farmas USA

AMRN http://www.fool.com/investing/2016/05/31/why-amarin-marketo-and-westar-energy-jumped-today.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2

Ir a respuesta

condep1002 01/06/16 07:06

Ha respondido al tema Farmas USA

http://www.fool.com/investing/general/2016/05/30/2-biotech-stocks-under-5-with-jaw-dropping-growth.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2

Ir a respuesta

condep1002 31/05/16 22:39

Ha respondido al tema Farmas USA

Amarin Announces FDA New Chemical Entity Market Exclusivity Determination for Vascepa(R) (icosapent ethyl) Capsules BEDMINSTER, NJ and DUBLIN, IRELAND--(Marketwired - May 31, 2016) - Amarin Corporation plc (NASDAQ: AMRN) announced today that the U.S. Food and Drug Administration (FDA) has determined that Vascepa® (icosapent ethyl) capsules are eligible for five-year, new chemical entity (NCE), marketing exclusivity pursuant to the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act. This determination provides Vascepa with the benefits of NCE exclusivity afforded by statute. NCE exclusivity for Vascepa runs from its date of FDA approval on July 26, 2012 and extends until July 26, 2017. The statutory 30-month stay triggered by patent litigation following generic application submissions permitted on July 26, 2016 would expire on January 26, 2020, seven-and-a-half years from FDA approval. "Amarin's goal is to protect the commercial potential of Vascepa to 2030," stated John F. Thero, president and chief executive officer of Amarin. "NCE regulatory exclusivity complements multiple patents covering Vascepa with expiration dates in 2030."

Ir a respuesta

condep1002 25/05/16 07:11

Ha respondido al tema Farmas USA

http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-novavax-inc-may-24-2016/

Ir a respuesta

condep1002 24/05/16 20:44

Ha respondido al tema Farmas USA

http://247wallst.com/healthcare-business/2016/05/23/10-speculative-biotech-and-biohealth-stocks-with-massive-analyst-upside-calls/ Amarin Amarin Corp. (NASDAQ: AMRN) was assumed with a Buy rating and a $3.50 price target (versus a $1.57 prior close) at Jefferies on May 12. The firm said it believes that the off-label Vascepa promotion in mixed dyslipidemia may be starting to bear fruit. It said: We believe off-label Vascepa promotion in mixed dyslipidemia may be beginning to bear fruit, where our analysis of TRx data suggests a steeper upward trend in recent months v. 2015. Access to this population is a major source of upside, where we see opportunity of $2.5 billion. Focus is also on REDUCE-IT where we believe Vascepa can show a benefit on final analysis in early 2018, and upside could be $14 per share. Read more: 10 Speculative Biotech and Biohealth Stocks With Massive Analyst Upside Calls - Amarin Corp plc (ADR) (NASDAQ:AMRN) - 24/7 Wall St. http://247wallst.com/healthcare-business/2016/05/23/10-speculative-biotech-and-biohealth-stocks-with-massive-analyst-upside-calls/#ixzz49bHOVIGF Follow us: @247wallst on Twitter | 247wallst on Facebook

Ir a respuesta